Click here to view the full activity and claim CPE credit: https://i3health.com/oda-mm-treatment

New technologies are leading to deeper responses and longer survival for patients with multiple myeloma. But these complex care plans lead to questions about how to optimize care. Clinicians are challenged with leveraging the best available evidence and meeting individual care needs in diverse patient populations across different settings. In this interview, Joseph Kalis, PharmD, BCOP, provides a preview of a continuing pharmacy education (CPE) activity he recently chaired for i3 Health, "Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma."